Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05789940

Hysteroscopy vs. Endouterine Aspiration in the Management of Trophoblastic Retention

Introduction: Incomplete early miscarriage is defined as early miscarriage with persistent intrauterine material on ultrasound. Intrauterine retention of trophoblastic debris is not an uncommon phenomenon. These retentions may initially be asymptomatic but are often responsible for persistent metrorrhagia and endometritis. This symptomatology often accentuates the psychological distress of patients mourning the pregnancy. Incomplete miscarriages are mainly managed by the gynecological emergency department. The recommendations of the Collège National des Gynécologues et Obstétriciens Français (CNGOF) suggest as a first line of treatment: either surgical management or expectant care. The choice between the two is left to the discretion of the doctor and the patient. there are no clear recommendations as to the choice between hysteroscopy and aspiration. Within the teams, the choice is often made according to the habits and protocols of the service, according to the equipment available and the skills of the gynaecologists.

Aim: The main objective is to compare the efficacy of management by endo-uterine aspiration vs. management by hysteroscopy of trophoblastic retention after early miscarriage, at 6 weeks after surgery, by endovaginal ultrasound.

Methods: This is a prospective, multicenter, randomized, open-label, two-arms, parallel therapeutic clinical trial comparing hysteroscopy versus endouterine aspiration for the management of trophoblastic retention after spontaneous miscarriage.

Patients will be randomized (110 per arm) after verification of eligibility criteria and signature of consent, on the day of the operation:

* Arm A: 110 patients treated by operative hysteroscopy * Arm B: 110 patients treated by endo-uterine aspiration

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–42 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

CHU de Bordeaux - Hôpital Pellegrin, Bordeaux, France

Loading trial locations.

About this study

Introduction: Incomplete early miscarriage is defined as early miscarriage with persistent intrauterine material on ultrasound. Intrauterine retention of trophoblastic debris is not an uncommon phenomenon. These retentions may initially be asymptomatic but are often responsible for persistent metrorrhagia and endometritis. This symptomatology often accentuates the psychological distress of patients mourning the pregnancy. Incomplete miscarriages are mainly managed by the gynecological emergency department. The recommendations of the Collège National des Gynécologues et Obstétriciens Français (CNGOF) suggest as a first line of treatment: either surgical management or expectant care. The choice between the two is left to the discretion of the doctor and the patient. there are no clear recommendations as to the choice between hysteroscopy and aspiration. Within the teams, the choice is often made according to the habits and protocols of the service, according to the equipment available and the skills of the gynaecologists.

Aim: The main objective is to compare the efficacy of management by endo-uterine aspiration versus management by hysteroscopy of trophoblastic retention after early miscarriage, at 6 weeks after surgery, by endovaginal ultrasound.

The secondary objectives are:

  • the comparison of the rate of complications of the two techniques, during and after surgery
  • the comparison of the rate of recourse to a second line surgical management between the two arms,
  • the comparison of the rate of synechiae diagnosed by hysterosonography between the two techniques at 6 weeks after surgery,
  • the comparison of the time to conception in the two arms during the 2 years after surgery
  • the comparison of the fertility rate at 2 years after surgery in the two arms.

Methods: This is a prospective, multicenter, randomized, open-label, two-arms, parallel therapeutic clinical trial comparing hysteroscopy versus endouterine aspiration for the management of trophoblastic retention after spontaneous miscarriage.

Patients will be randomized (110 per arm) after verification of eligibility criteria and signature of consent, on the day of the operation:

  • Arm A: 110 patients treated by operative hysteroscopy
  • Arm B: 110 patients treated by endo-uterine aspiration Randomization will be stratified by center, age (<35 years, 35 years and over), size of trophoblastic retention (<30mm, 30mm and over) and scheduled by random size block. It will be centralized (Ennov-clinical software) and parameterized by the Unité́ de Recherche Clinique & Biostatistiques of the Montpellier University Hospital.

Statistics: The effectiveness of operative hysteroscopy is expected to be 100%, and that of aspiration 90%. To show this difference with an alpha risk of 5%, and with a power of 90%, 98 patients per arm will have to be analysed (exact binomial distribution calculation, epiR package of R implemented in biostatgv). To take into account a 10% loss of sight rate, 220 patients will be recruted.

Patients will be included in the study on the morning of the procedure, after verification of the selection criteria.

The expected number of lost to follow-up is estimated at 10%; in fact, the main criterion is evaluated relatively early (6 weeks), in patients having a desire for pregnancy and therefore relatively compliant, the rate of lost to follow-up will be a fairly low.

A flow-chart will be constructed to describe the evolution of the populations during the study. It will detail the causes of non-inclusion and the causes of loss to follow-up.

All study data will be described according to the randomization arm, in the randomized population: mean, standard deviation, median and quartiles, extrema and number of missing data for quantitative variables, numbers and percentages of each modality for qualitative data.

The clinical comparability of the randomized population and the ITT population for the primary endpoint will be assessed.

Primary analysis:

The uterine vacuity rate will be compared between the two arms in the ITT population for the primary endpoint by a Chi-square test or by a Fisher exact test if the conditions for Chi-square validity are not met. The significance level was set at 5%, two-sided.

Secondary endpoint analysis:

The rates of complications, use of second-line surgical management, synechiae, and fertility at 2 years after surgery will be compared between the two arms in their respective ITT populations, by a Chi-square test or by a Fisher's exact test if the conditions for the validity of Chi-square are not met.

The time to conception will be compared between the two arms of the randomized population by a log-rank test.

Within this family of endpoints, the alpha risk will be controlled by a Hochberg procedure.

Visit 1: Pre-operative consultation between 1 and 21 days before the operation

  • Clinical examination performed as part of routine care: measurement of blood pressure and pulse, temperature, speculum examination to ensure the absence of significant bleeding indicating emergency surgical management.
  • Diagnosis of trophoblastic retention by endovaginal ultrasound

At the end of the consultation:

  • Verification of eligibility criteria
  • Oral information on the study and information leaflet given to the patient
  • Collection of informed and written consent after a reflection period
  • Collection of the following data:
  • Demographic data
  • History, smoking habits and concomitant treatments
  • Pregnancy data leading to the current miscarriage
  • Results of pelvic ultrasound

Intervention (D0):

  • Verification of eligibility criteria and randomization on the morning of the procedure
  • Surgical management of trophoblastic retention by operative hysteroscopy (Arm A) or endo-uterine aspiration (Arm B)
  • Collection of adverse events during the operation and before the patient is discharged

Visit 2: Consultation at 6 weeks after surgery +/- 7 days

This consultation will be performed by an investigator trained in pelvic ultrasound and hysterosonography, blinded to the allocated procedure:

  • Plasma HCG measurement before hysterosonography to ensure that there is no current pregnancy
  • Endovaginal ultrasound to check uterine vacuity
  • Hysterosonography for the diagnosis of uterine synechia
  • Collection of complications and adverse events after surgery

Visit 3: Telephone consultation at 6 months +/- 15 days after surgery

Carried out by the clinical research associate (CRA):

  • Evaluation of fertility by questionnaire
  • Evaluation of the time to conception if pregnancy in progress A letter will be sent to the patient if she cannot be reached by phone (questionnaire + return envelope)

Visit 4: Telephone consultation at 12 months +/- 1 month after surgery

Carried out by the CRA:

  • Evaluation of fertility by questionnaire.
  • Evaluation of the time to conception if pregnancy in progress. A letter will be sent to the patient if she cannot be reached by phone (questionnaire + return envelope)

Visit 5: Telephone consultation at 24 months (+/- 2 months) after surgery

Carried out by the CRA:

  • Evaluation of fertility by questionnaire
  • Evaluation of the time to conception if pregnancy in progress A letter will be sent to the patient if she cannot be reached by phone (questionnaire + return envelope). The patients will be followed until a pregnancy is obtained with a term greater than or equal to 24 weeks of amenorrhea or over a maximum period of 26 months after the surgery.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Management for trophoblastic retention after early spontaneous miscarriage (<14 weeks of amenorrhea)
  • Diagnosis of intrauterine trophoblastic retention by endovaginal pelvic ultrasound
  • Shared decision for surgical management

Exclusion criteria

  • Known uterine malformation
  • Patient who has received surgical treatment for current intrauterine retention
  • Patient with an intrauterine device (IUD)
  • Pregnancy obtained by medically assisted procreation
  • Indication for emergency surgical management for haemostatic purposes
  • Failure to obtain free, informed and written consent after a period of reflection
  • Person not affiliated or beneficiary of a national health insurance system
  • Person protected by law, under guardianship or curatorship
  • Person participating in other interventional research involving the human person

Treatment and study plan

Hysteroscopy

Procedure

The procedure is performed by a gynecologic surgeon under general or spinal anesthesia, depending on the standard practice of the center involved, with the patient in the gynecologic position. Antibiotic prophylaxis may be administered according to the standard practice of the center. The equipment available at each center will be used for operative hysteroscopy. The use of energy is usually unnecessary and saline will be preferred. Before the operation, the appearance of the uterine cavity will be described. The selected design product will be resected from top to bottom using the surgical resector, without electrical energy, as this method is known to be the most protective of the endometrium in previous studies. Electric current should be used only as a last resort, in cases where the selected design cannot be removed without it. If there is active bleeding after the procedure, elective coagulation via the hysteroscope may be performed to stop intrauterine bleeding.

Aspiration

Procedure

The aspiration will be performed by a gynecological surgeon, according to the center's standard protocol. A flexible or rigid cannula can be used. Antibiotic prophylaxis, the diameter of the cannula used, the cervical preparation required, and the use of intraoperative ultrasound guidance will be left to the discretion of the operator and the standard practice of the center. In most centers, the cervix is dilated with a Hegar dilator of up to 9 mm in size.

Primary outcomes

  1. Uterine vacuity

    Time frame: 6 weeks after surgery

    Uterine vacuity will be determined by endovaginal pelvic ultrasound. The endovaginal pelvic ultrasound will be performed by an investigator blinded to the patient's group, in order to minimize bias. It will be performed according to a standard pelvic ultrasound technique: a sagittal section and a transverse section passing through the widest part of the uterine body. Uterine vacuity will be defined by a thickness of the mucosa on a sagittal section of 15 mm or less and the absence of a heterogeneous intrauterine mass

Secondary outcomes

  1. Difference between the two arms in complication rates

    Time frame: During surgery and 6 weeks after surgery

    Complications will be described according to clavien-dindo classification

  2. Difference between the two arms in the rate of second line surgical management

    Time frame: During surgery

    The rate of second line surgical management will be described

  3. Difference between the two arms in synechia rates

    Time frame: 6 weeks after surgery

    Presence of synechia will be assessed by hysterosonography

  4. Difference between the two arms in mean time to conception

    Time frame: 6, 12 and 24 months after surgery

    Patients will be contacted by phone at 6, 12 and 24 months after the surgery to ask if they have been pregnant et evaluate the time of conception

  5. Difference between the two arms in pregnancy rates

    Time frame: 6, 12 and 24 months after surgery

    Patients will be contacted by phone at 6, 12 and 24 months after the surgery to assess their fertility

Study contacts

Contact information is provided by the study sponsor or research team.

Elodie GUIBERT, CRA

CONTACT

[email protected]

+334 67 33 53 17

Martha DURAES, MD

CONTACT

[email protected]

+334 67 33 65 32

Sponsors and collaborators

Lead sponsor

University Hospital, Montpellier

Other

Registry information

Official study title

Hysteroscopy Versus Endouterine Aspiration in the Management of Trophoblastic Retention: A Prospective Randomized Multicenter Study

Acronym: HARET

Important dates

Study start
2023
Primary completion
2027
Study completion
2029
First posted
Mar 29, 2023
Registry last updated
Jun 22, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.